

Claims

1. Use of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of nonconstipated female IBS.

5 2. Use according to claim 1 wherein the 5-HT<sub>3</sub> receptor antagonist is alosetron or a pharmaceutically acceptable derivative.

3. Use according to claim 2 wherein alosetron is in the form of its hydrochloride.

10 4. Use according to claim 1 wherein the 5-HT<sub>3</sub> receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, Ierisetron, (R) zacopride, cilansetron, itasetron, indisetron or dolasetron.

5. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof.

15 6. A method of treatment according to claim 5 wherein the 5-HT<sub>3</sub> receptor antagonist is alosetron or a pharmaceutically acceptable derivative.

7. A method of treatment according to claim 6 wherein alosetron is in the form of its hydrochloride.

20 8. A method of treatment according to claim 5 wherein the 5-HT<sub>3</sub> receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, Ierisetron, (R) zacopride, cilansetron, itasetron, indisetron or dolasetron.

9. A 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of nonconstipated female IBS.

25 10. A 5-HT<sub>3</sub> receptor antagonist according to claim 9 which is alosetron, or alosetron in the form of its hydrochloride.

Add A2  
Add B3